<DOC>
	<DOC>NCT01134549</DOC>
	<brief_summary>The purpose of this study is to characterize the safety and tolerability of KAI-4169 in healthy young males.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Male between 18 and 45 years of age who have provided written informed consent Subject is judged to be in good health based on medical history, physical examination, and routine laboratory tests History or presence of any significant acute or chronic illness (e.g., cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease) according to the investigator History of any ongoing medical condition requiring treatment with prescription medication History of asthma, severe allergies including skin reactions or prior anaphylactic type reactions Clinically significant abnormalities on screening clinical examination or laboratory safety tests History of drug or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Phase 1 Clinical Trials</keyword>
</DOC>